Evidence map›Paper›PMID 41209833›Full record

ArticleJournal of ophthalmology2025

Topical Povidone Iodine 2.5% Versus 5% for Endophthalmitis Prophylaxis During Intravitreal Injections.

Radwan S Ajlan, Shreeya Dalla, Riya J Parikh, Matthew M Pfannenstiel, Mary T Champion, Md Atikur Rahman, Francisco J Diaz

Abstract read
In one paragraph

Article in Journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Radwan S AjlanDepartment of Ophthalmology, University of Kansas School of Medicine, Kansas City, Kansas, USA.ORCID https://orcid.org/0000-0002-5048-327X
Shreeya DallaDepartment of Ophthalmology, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Riya J ParikhDepartment of Ophthalmology, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Matthew M PfannenstielDepartment of Ophthalmology, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Mary T ChampionDepartment of Ophthalmology, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Md Atikur RahmanDepartment of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.
Francisco J DiazDepartment of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.ORCID https://orcid.org/0000-0003-4090-228X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Topical povidone iodine (PI) has been shown to reduce the risk of endophthalmitis following intravitreal injections (IVIs). However, PI is a known ocular irritant and can result in significant eye discomfort. Currently, 5% PI is the most used concentration for ocular surface disinfection prior to IVI. 2.5% PI has been proposed as an alternative IVI preparation to lessen PI-associated ocular irritation. The purpose of this study is to compare the efficacy of topical PI 2.5% to PI 5% in preventing post-IVI endophthalmitis at a single academic institution location. Methods: A retrospective chart review was conducted at a single academic institution location of patients receiving IVI from August 1st, 2017, to June 15th, 2022. IVIs were performed using PI 2.5% or PI 5%. PI 5% was applied to the ocular surface 60 s before IVI. PI 2.5% was applied over the ocular surface and then reapplied 4-5 min later over the injection site and fornices before IVI. Results: A total of 7360 IVIs were performed in 773 patients (473 patients on 2.5% and 300 on 5% PI). 52.0% of IVIs were performed with 2.5% PI ( Conclusion: In this retrospective study, we found that 2.5% and 5% PI had similar results in preventing post-IVI endophthalmitis. This study adds to the literature by further supporting the antiseptic effect of 2.5% PI for IVI. Larger prospective studies are needed to further clarify the antiseptic effect and ocular surface irritation associated with 2.5% PI use.

Identifiers

PMID41209833
PMCPMC12591801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.